An interventional study of Culturally Adapted Portfolio Diet Health Education Programme in Dyslipidemias and Hyperlipidemias, sponsored by The Hong Kong Polytechnic University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Hyperlipidemias with a site in China — 30 open to participants now, 38 under way, 7 of them phase 3. Hyperlipidemias · China.
Among the 95 studies in Hyperlipidemias with a site in China, this one is the 76th largest by planned enrollment of the 79 interventional ones that give a count, is the only one that started in 2027, is one of 21 with no phase, reaches primary completion later than 26 of the 37 other live ones, and was the 95th registered.
862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.
Browse Hyperlipidemias studies →30 of the 95 studies in Hyperlipidemias with a site in China are open now. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–79
Jianyin Zhou · Sites in China
Ages 18–65
Beijing Suncadia Pharmaceuticals Co., Ltd · Sites in China
Ages 18+
Shanghai 10th People's Hospital · Sites in China
Ages 18–60
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 66 Hyperlipidemias studies recruiting now, 26 (39%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 12 · Phase 3 20 · Phase 4 7
First in 2005; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 150 across the 79 interventional studies, 1,151 across the 16 observational. Of the 44 that completed or were terminated, 4 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 95 have an industry lead sponsor. The 10 most frequent:
The Hong Kong Polytechnic University is the lead sponsor of 683 studies on the registry; 261 are open to participants now.
The Hong Kong Polytechnic University has 1 study filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
10 of the studies in Hyperlipidemias with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT07230730Phase 3Beijing Suncadia Pharmaceuticals Co., LtdA Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia | 2027-10 |
| NCT05457582Nanjing First Hospital, Nanjing Medical UniversityPCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | 2026-12-30 |
| NCT07938099Xin LiReal-World Study Comparing PCSK9 Monoclonal Antibody With Cholesterol Absorption Inhibitors in Patients With ASCVD for Secondary Prevention | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 95 studies in Hyperlipidemias with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background:
Dyslipidemia (raised blood cholesterol) is a widespread public health concern in Hong Kong. While medications like statins are commonly used, many individuals hesitate to take them, making effective dietary strategies essential for reducing cardiovascular disease risk. The Portfolio Diet is a proven plant-based dietary pattern that can significantly lower cholesterol levels, but its feasibility has not yet been thoroughly explored or culturally adapted for a non-Western population like Hong Kong.
Purpose:
This feasibility study aims to evaluate whether a culturally tailored Portfolio Diet health education programme is practical, acceptable, and effective for Hong Kong adults with dyslipidemia. The findings will help researchers understand the practical challenges and motivators participants face when trying to change their diet, which will guide the design of a future larger-scale trial.
Methods:
A total of 12 Chinese adults aged 18 to 65 with borderline or high total cholesterol will participate in a 4-week health education programme. The programme begins with a group session explaining the core dietary principles, followed by 3 weekly individual dietary consultations with a research dietitian. The diet plan and sample 7-day menus are culturally adapted to include food items commonly consumed in Chinese culture.
Participants' diet adherence will be assessed using 3-day dietary records at the beginning and end of the study. Additionally, researchers will track feasibility data such as recruitment and retention rates, session attendance, and the completeness of the dietary records. Following the 4-week programme, participants will join focus group interviews to share their personal feedback, experiences, and suggestions for improving the programme for long-term use.
Background and Rationale:
Dyslipidemia is a major public health challenge in Hong Kong, affecting over half of the adult population. While standard management relies on lifestyle advice and pharmacotherapy (e.g., statins), patient hesitancy toward medication remains a significant barrier. The Portfolio Diet-a dietary pattern combining four cholesterol-lowering components (viscous fibers, plant sterols, plant proteins, and nuts)-has demonstrated clinical efficacy in reducing serum low-density lipoprotein-cholesterol (LDL-C) by a mean of 28.6% in Western cohorts. However, its feasibility, acceptability, and efficacy signal have not been explored in non-Western populations whose local dietary habits differ significantly. This feasibility study is a necessary prerequisite to adapt the dietary components into Chinese culture and inform the design of a future full-scale randomized controlled trial (RCT).
Objectives:
Study Design and Interventions:
This is an interventional feasibility study utilizing a single-group, pre-post test design combined with a qualitative component. Twelve eligible Chinese adults with dyslipidemia will undergo a 4-week health education programme:
Qualitative Component:
Post-intervention, all 12 participants will be divided into two focus groups (6 participants per group) for a 1-hour semi-structured interview conducted by a trained research assistant. The interviews will be audio-recorded and will systematically explore four domains: programme acceptability, dietary changes and practicality, perceived benefits, and suggestions for long-term implementation in Hong Kong.
Data Collection and Dietary Analysis:
Quantitative clinical and socio-demographic data will be collected at baseline and at week 4 (post-intervention). Dietary adherence will be assessed using 3-day dietary records (2 weekdays and 1 weekend day) completed at both time points. Nutrient and individual component intakes will be rigorously analyzed using Food Processor Nutrition Analysis and Fitness software (Version 8.0, ESHA Research), utilizing localized food composition tables from China and Hong Kong to ensure accuracy.
862 studies on the registry are indexed under Hyperlipidemias; 108 are open to participants now.
This study's planned enrollment of 12 is below the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →The Hong Kong Polytechnic University is the lead sponsor of 683 studies on the registry; 261 are open to participants now.
Compared within Hyperlipidemias, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single group of 12 Hong Kong Chinese adults with dyslipidemia who receive a culturally adapted 4-week Portfolio Diet health education programme, followed by qualitative focus group interviews.
Behavioral: Culturally Adapted Portfolio Diet Health Education Programme
The programme consists of 4 weekly sessions. Week 1 is a group-based session introducing the principles of the Portfolio Diet and its clinical relationship with cardiometabolic health. Weeks 2 to 4 consist of 3 individual dietary consultations conducted by a research dietitian. The dietary components (nuts/seeds, plant protein, viscous fiber, plant sterols, and plant-based fats) are culturally adapted to commonly consumed food groups in Chinese culture. Participants receive a localized 7-day menu to help modify their diet.
Programme Retention Rate
The percentage of enrolled participants who successfully complete the entire 4-week health education programme. This metric is used to evaluate the feasibility of the study protocol and participant retention.
Time frame: At the end of the 4-week intervention
Change in Portfolio Diet Adherence Score
Assessed by 3-day dietary records (covering 2 weekdays and 1 weekend day) to evaluate the change in participant adherence to the Portfolio Diet pillars. Nutrient and dietary component intakes will be analyzed using Food Processor Nutrition Analysis and Fitness software (Version 8.0) with localized food composition tables.
Time frame: Baseline and Post-intervention (Week 4)
Participant Acceptability and Perceived Barriers via Focus Groups
Evaluated through post-intervention qualitative focus group interviews (6 participants per group). A semi-structured interview guide will be used to explore four core domains: acceptability of the programme format/duration, dietary changes and practical challenges, perceived health benefits, and suggestions for long-term implementation.
Time frame: Post-intervention (Week 4)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — As this is a small-scale pilot feasibility study (N=12) focused on evaluating protocol processes and cultural acceptability, individual participant data will not be made publicly available to protect participant privacy.
Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.
Of 166 non-industry interventional studies with no phase under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 11 months is below that.
Counting every sponsor, half of 171 studies reached it within 15 months; a quarter within 7 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hong Kong Polytechnic University →